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Background: Microbial translocation is associated with immune activation in 
chronic HIV-1 infection and may provoke endothelial dysfunction. We examined 
the relationship between surrogate markers of microbial translocation, 
endothelial activation and immune activation in Primary HIV-1 infection (PHI) 
and assessed whether short course ART given in PHI impacts on these 
biomarkers after stopping treatment.  
Methods: Plasma samples from 90 UK and Australian SPARTAC participants 
recruited within 6 months of HIV seroconversion and randomised to 12 or 48 
weeks ART, or no ART, were analysed for surrogate markers of microbial 
translocation (LPS-Binding Protein (LPB), soluble CD14 and Endotoxin Core 
Antibody (EndoCab) at baseline and week 60. Results were correlated with 
markers of inflammation, coagulation and endothelial activation (IL-6, D-dimer, 
soluble tissue factor, ICAM-1) and CD4 and CD8 T-cell activation (CD38 and 
HLA DR) using Spearman rank correlations. Biomarker levels at week 60 and 
change from baseline were compared between arms using linear regression 
analyses. Samples from 30 healthy controls were also analysed at a single time 
point and compared to SPARTAC week 0 and 60 using Mann-Whitney U tests.  
Results: In SPARTAC participants at week 0 there was a significant association 
between LPB and IL-6 (rho=0.4, p<0.001), between sCD14 and D-dimer 
(rho=0.3, p=0.01) and between sCD14 and sICAM (rho=0.3, p=0.004). These 
associations remained at week 60. 
At SPARTAC week 0, no relationship was seen between T cell activation and 
markers of microbial translocation. However at week 60, sCD14 and EndoCAb 
correlated with CD4 T-cell activation (e.g. sCD14 and CD4 HLADR% rho=0.4, 
p<0.001; EndoCab and dual CD4 CD38 HLADR% rho=0.3, p=0.01) and LBP 
weakly correlated with CD8 T-cell activation.  
No difference was seen between SPARTAC arms at week 60 comparing those 
who received either 12 or 48 weeks ART and those randomised to no ART.  
LBP and sCD14 were raised in SPARTAC patients compared to healthy controls 
at week 0 and week 60 (p<0.001 for sCD14; p=0.002 at week 0, p=0.02 at week 
60 for LPB). 
Conclusion: Surrogate markers of microbial translocation were raised in HIV+ve 
patients compared to healthy controls. In SPARTAC, these markers were 
associated with T cell activation at week 60 but not at seroconversion. 48 weeks 
of ART did not impact LPS activity at 60 weeks after PHI, 12 weeks after 
treatment interruption; this analysis was however limited by small numbers. 
 
